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involved in the mechanism of typical and atypical neuro-
leptic drugs.
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Introduction
Schizophrenia is characterized by changes in structural 
network connectivity, which are associated with the nerve 
cell bodies (synapses, dendrites and axons) as well as with 
the glial cells. Many studies have shown that structural and 
functional abnormalities in all three types of glial cells 
influence the pathogenesis of schizophrenia. There is evi-
dence for reduced numbers of oligodendrocytes, impaired 
cell maturation and altered expression of astrocyte-related 
genes, such as reduced expression of GFAP mRNA or glu-
tamine synthetase in schizophrenic patients [1, 2]. Due to 
the important role of glial cells in the pathology of schizo-
phrenia, efforts to develop glia-directed therapies for the 
treatment of schizophrenia have been discussed.
Existing antipsychotic drugs improve the negative and 
positive symptoms of schizophrenia through complex 
mechanisms that are not completely understood [3, 4]. It is 
known that they act through the modulation of monoamin-
ergic neurotransmission, primarily involving the dopamin-
ergic pathways [5]. However, studies indicate that antip-
sychotic drugs used in clinical practice, exert a positive 
influence on the astrocyte metabolism, which is disturbed 
in schizophrenia, by binding to astrocyte dopamine recep-
tors and interacting with a wide range of cell compounds 
[6]. Recent studies have suggested that the neuroprotective 
action of neuroleptic drugs is mediated by their regulatory 
influence on both neurotrophic factors and neuropeptides, 
Abstract Several lines of evidence suggest that pituitary 
adenylate cyclase-activating polypeptide (PACAP) is a neu-
ropeptide playing an important role as a neuromodulator. 
It has been indicated that PACAP is associated with men-
tal diseases, and that regulation of the PACAPergic signals 
could be a potential target for the treatment of such psy-
chiatric states as schizophrenia. Recent studies have sug-
gested that action of neuroleptic drugs is mediated not only 
by dopaminergic and serotonergic neurotransmission, but 
also via neuropeptides which may act both as neurotrans-
mitters and as neuromodulators. The present study exam-
ines whether currently-used neuroleptics influence the 
action of PACAP receptors, whose expression is altered in 
a schizophrenic patient. Real-time polymerase chain reac-
tion (PCR) was used to examine the effects of haloperidol, 
olanzapine and amisulpride on the expression of genes 
coding PAC1/VPAC type receptors in the T98G glioblas-
toma cell line, as an example of an in vitro model of glial 
cells. PAC1 mRNA expression fell after 24-h incubation 
with haloperidol or olanzapine; however the effect was not 
maintained after 72  h, and haloperidol even up-regulated 
PAC1 mRNA expression in a dose-dependent manner. 
All the examined drugs decreased VPAC2 mRNA expres-
sion, especially after 72-h incubation. Haloperidol (typical 
neuroleptic) was distinctly more potent than atypical neu-
roleptic drugs (olanzapine and amisulpride). In addition, 
PACAP increased PAC1 and VPAC2 mRNA expression. In 
conclusion, our findings suggest PACAP receptors may be 
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which may act both as neurotransmitters and as neuro-
modulators [7–9]. The prominent one among the neuropep-
tides, which antipsychotics can affect is pituitary adenylate 
cyclase-activating polypeptide (PACAP) [10]. Nowadays, 
the signaling system of PACAP is extensively studied due 
to its pleiotropic involvement in various physiological and 
pathological conditions.
PACAP is a member of a structurally-related family of 
peptides whose numbers include vasoactive intestinal pep-
tide (VIP), secretin, glucagon, growth hormone-releasing 
hormone (GHRH) and peptide histidine–isoleucine (PHI), 
all being involved in the modulation of numerous biologi-
cal functions in vertebrates [11]. PACAP is implicated in 
such phenomena as neurotransmission, neural plasticity, 
and neurotrophy. It is also endowed with neuroprotective 
potential [12, 13]. The biological effects of PACAP are 
mediated by three types of G-protein- coupled receptors 
(GPCRs), namely PAC1 type (including at least eight dif-
ferent splice variants) and VPAC type (including VPAC1 
and VPAC2 subtypes). PAC1 receptors display higher 
affinity for PACAP than for VIP, while VPAC type recep-
tors bind both peptides similarly and with high affinity [14]. 
The adenylyl cyclase (AC)/cyclic AMP (cAMP) is the main 
intracellular signal transduction pathway coupled with all 
mentioned types of receptors and its dysfunction has been 
implicated in schizophrenia [15–17].
PACAP and its receptors have been observed to display 
abnormal activity in a number of psychiatric disorders 
[14]. The PACAP gene is located on 18p11. Various stud-
ies suggest the existence of a link between this locus and 
schizophrenia [18]. Genetic variants of the genes encoding 
PACAP and PAC1 have been described in schizophrenic 
patients [19]. Moreover, the results of recent genetic stud-
ies indicate increased VPAC2 receptor expression in schiz-
ophrenia [20, 21]. These pharmacological studies suggest 
that the regulation of PACAP signaling may be a potential 
therapeutic target for the development of novel antipsy-
chotic drugs [19].
Therefore, the goal of the current paper was to deter-
mine the involvement of PACAP in the therapeutic mecha-
nism of neuroleptic drugs, known to be complex, in cells of 
nonneuronal origin. The study examines the effect of these 
drugs on the expression of genes coding PAC1/VPAC type 
receptors in the T98G glioblastoma cell line, as an example 
of an in vitro model of glial cells, with a typical drug being 
haloperidol (dopamine D2—receptor antagonist), and two 
atypical drugs being olanzapine (serotonin 5-HT2A—recep-
tor antagonist and weak dopamine D2—receptor antago-
nist) and amisulpride (assigned to the group of atypical 
neuroleptic drugs but it exhibits poor affinity for the sero-
tonin 5-HT2A—receptor). Additionally, for the purposes 
of comparison, the effect of exogenous PACAP38 on its 
receptors was also evaluated.
Materials and Methods
T98G glioma cell line was purchased from the American 
Type Culture Collection (ATCC; Rockville, MD, USA). 
The cells were cultured in 25-ml flasks in medium com-
posed of Advanced MEM supplemented with 10% fetal 
bovine serum, 2 mM glutamine and a penicillin–streptomy-
cin solution, in a humidified atmosphere of 95% air and 5% 
CO2 at 37 °C. For subcultures, cells were harvested every 
third day in trypsin-EDTA (0.25% trypsin, 1 mM EDTA) 
solution. For the gene expression assay, T98G cells were 
plated onto six-well plates (Nunc) at a density of 3 × 105 
cells per well. For the cell viability assay, the cells were 
seeded onto 96-well plates, at the density of 5 × 104 cells 
per well. The following substances were used: fetal bovine 
serum, penicillin–streptomycin solution (5000 units/ml 
penicillin and 5000  g/ml streptomycin sulphate in nor-
mal saline), phosphate buffered saline (PBS; pH 7.4) and 
trypsin–EDTA were purchased from Invitrogen (Carlsbad, 
CA, USA). Advanced MEM was obtained from Gibco 
(Paisley, Scotland, UK).
Drug and Peptide Treatments
T98G cells were treated with the neuroleptic drugs halop-
eridole, clozapine, amisulpride (Sigma-Aldrich, St. Louis, 
Mo., USA), and with peptide PACAP38 (H-8430, Bachem) 
and incubated for 24 and 72  h. All the neuroleptic drugs 
were initially dissolved in DMSO followed by a prepara-
tion of working concentrations in an appropriate medium. 
Control samples were treated with medium with DMSO in 
an amount corresponding to the concentration of the used 
drugs. The medium was changed every 2  days prior to 
drug/peptide treatment.
MTT Conversion
The evaluation of cell viability was performed using the 
MTT conversion method. Mitochondrial succinate–tetra-
zolium reductase system converts yellow tetrazolium MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, Sigma-Aldrich) into purple formazan. T98G cells 
were subjected to 24 and 72-h incubation with neuroleptic 
drugs or without the tested chemicals (control group). After 
incubation, 50 µl MTT (1 mg/ml) was added and the plates 
were incubated at 37 °C for 3 h. At the end of the experi-
ment, the cells were exposed to 100 µl dimethyl sulphoxide, 
which enabled the dissolution of formazan. The absorbance 
at 570 nm was read on a microplate reader and the results 
were expressed as a percentage of the absorbance measured 
in control cells.
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Total RNA Extraction and cDNA Generation
Total RNA extractions were carried out using RNe-
asy Mini kit (Qiagen) according to the manufacturer’s 
instructions. RNA content was measured using a Pico-
Drop spectrophotometer (Picodrop Limited). The qual-
ity of RNA samples was analyzed by measuring the 
absorption ratio at 260/280  nm. The purified total RNA 
was immediately used for cDNA synthesis or stored at 
−80 °C.
cDNA was generated with QuantiTect Reverse Tran-
scription Kit (Qiagen) according to the manufacturer’s 
protocol. Samples of 1  μg of total RNA were used as 
starting material, reverse transcription was performed in 
the conditions optimized for use with the kit (42 °C for 
30 min, 95 °C for 3 min). The cDNA samples were kept 
frozen at −20 °C.
Real Time PCR
Gene expression was measured using the TaqMan kit. 
Briefly, the reactions were performed in 10  μl amounts 
including 50 ng cDNA, 5 μl KAPA PROBE FAST qPCR 
Kit Master Mix ABI Prism (Kapa Biosystems) and 0.5 μl 
appropriate TaqMan Gene Expression Assay (20×). Spe-
cific Pre-made TaqMan assays were used in this study: 
adenylate cyclase activating polypeptide 1 (pituitary) 
receptor type I (ADCYAP1R1, Applied Biosystems code-
Hs01027974_m1), vasoactive intestinal peptide recep-
tor 2 (VIPR2, Hs00173643_m1), and beta actin (ACTB, 
Hs01060665_g1) as the endogenous control. TaqMan 
PCR assays were performed on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems) in FastGene Fast 96 
well PCR plates (Nippon Genetics Europe GmbH). The 
following thermal cycling specifications were performed: 
20 s at 95 °C and 40 cycles each for 3 s at 95 °C and 30 s 
at 60 °C. Real-time PCR data was analyzed using the 
2−ΔΔCt method [22].
Assay of cAMP Formation
The formation of [3H]cAMP was measured in [3H]ade-
nine prelabeled T98G cells as previously described in 
detail by Jozwiak-Bebenista et al. [23] and Nowak et al. 
[24].
Data Analysis
The results were expressed as the mean ± standard error 
of the mean (SEM) values and were analyzed for statisti-
cal significance using one-way ANOVA, followed by the 
post hoc Student-Newman-Keul’s test. All parameters 
were considered significantly different if p < 0.05. The 
statistical analysis was performed using Statgraphics 5.0 
plus software (STSC Inc., Rockville, MD, USA).
Results
Effects of Neuroleptics on the Viability of T98G Cells
In order to assess the effects of neuroleptics on cell via-
bility, the cells were seeded on 96-well plates and treated 
with various concentrations of drugs or vehicle for 24 or 
72  h. Following the incubation period, cell viability was 
measured (Fig. 1). The results revealed that the 24-h treat-
ment with the highest concentrations of haloperidol (50 
and 100  µM) caused a marked reduction of cell viability 
(72% and 68% compared to control value, respectively). 
Neither the 24-h nor 72-h incubation of cells treated with 
0.1–100  μM olanzapine had any effect on cell viability 
relative to control cells. Indeed, on the basis of the results 
of the present and comparison studies, it was decided not 
to evaluate the highest concentrations of haloperidol or 
olanzapine (50 and 100 µM) on gene expression. Similar to 
olanzapine, amisulpride was not found to affect cell viabil-
ity for either incubation time when used at concentrations 
ranging from 0.1 to 100 μM.
Effects of Neuroleptics on PAC1 Expression in T98G 
Cells
The effect of haloperidol, olanzapine and amisulpride on 
PACAP specific receptors PAC1 gene expression was eval-
uated in a T98G glioblastoma cell line. The cells were incu-
bated with 5 or 20 µM haloperidol or olanzapine and with 
20 or 100 µM amisulpride for 24 or 72 h. After the incuba-
tion period, total RNA was extracted and subjected to gene 
expression studies.
The 24-h incubation with 20 µM haloperidol and olan-
zapine caused a statistically significant reduction of PAC1 
mRNA expression (Fig. 2a, b; *p < 0.05). The 72-h incuba-
tion resulted in the up-regulation of PAC1 mRNA expres-
sion by haloperidol in a dose dependent manner. Halop-
eridol administered at 5  µM increased the level of PAC1 
mRNA expression by 1.8 times and 20 µM by as much as 
2.5 times (Fig. 2c, d; **p < 0.01 and ***p < 0.001). Like-
wise, although 5 µM olanzapine caused a similar increase 
in PAC1 expression to haloperidol, no change in PAC1 
mRNA expression was revealed at the higher concentration 
(20 µM) (Fig. 2c, d; *p < 0.05). No statistically significant 
effect was found for 20 and 100 µM amisulpride on PAC1 
expression after either 24-h or 72-h incubation (Fig. 2).
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Effects of Neuroleptics on VPAC2 Expression in T98G 
Cells
To determine the effect of haloperidol, olanzapine and 
amisulpride on PACAP-specific receptors, VPAC2 gene 
expression was evaluated in a T98G glioblastoma cell 
line. The cells were incubated with 5 and 20 µM haloper-
idol or olanzapine, or with 20 or 100 µM amisulpride for 
24 or 72  h. After the incubation period, total RNA was 
extracted and subjected to gene expression studies.
The 24-h incubation with 20  µM haloperidol and 
olanzapine caused a statistically significant reduction 
of VPAC2 mRNA expression (Fig.  3a, b; ***p < 0.001 
and **p < 0.01). After a 72-h incubation, the observed 
diminished effect was maintained by 20  µM olanzapine 
and further decreased by 20  µM haloperidol (Fig.  3d; 
***p < 0.001); however, no effect was observed with the 
lower concentration of haloperidol. Interestingly, 5  µM 
olanzapine exhibited the opposite effect to higher con-
centration of the drug, causing slight up-regulation of 
VPAC2 (Fig. 3c; *p < 0.05).
The 24-h incubation with amisulpride had no effect on 
VPAC2 expression. After 72  h, 20 and 100  µM amisul-
pride caused a weak reduction in VPAC2 mRNA expres-
sion (Fig. 3).
Effect of PACAP38 on PAC1 and VPAC2 Expression 
in T98G Cells
In parallel, the effect of exogenous PACAP38 on its spe-
cific receptors PAC1 and VPAC2 gene expression was 
evaluated in this cell model. The T98G cells were treated 
with 1 µM PACAP38 for 24 or 72 h.
For both incubation times, PACAP38 significantly up-
regulated PAC1 and VPAC2 mRNA expression in T98G 
cells (Fig. 4a, b; *p < 0.05 and ***p < 0.001). PACAP38 
was found to have its strongest stimulatory effect on 
VPAC2 mRNA expression. After a 24-h incubation with 
peptide, a five-fold up-regulation of VPAC2 mRNA 
expression was observed compared to the control group 
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Fig. 1  Concentration-dependent effect of neuroleptics (a haloperidol, 
b olanzapine, c amisulpride) on viability of T98G cells. After 24 and 
72 h incubation with the neuroleptic drugs (0.1–100 µM) cell viabil-
ity was analyzed by MTT test. The results are expressed as percent-
age of control. Values are the mean ± SEM (n = 6–9)





























































































































Fig. 2  The effects of haloperidol (5 and 20 µM), olanzapine (5 and 
20  µM) and amisulpride (20 and 100  µM) on PAC1 expression in 
T98G cell line. Cells were incubated with neuroleptic drugs for 24 h 
(a, b) or 72 h (c, d) and subjected to gene expression studies. Con-
trol cells were treated with medium. 1 µg of total RNA isolated from 
cells was reverse transcribed and 50  ng of cDNA was used for the 
real-time PCR analysis. All real-time PCR reactions were performed 
in duplicate, using ACTB gene as an endogenous normalization fac-
tor. Results are expressed as relative units (r.u.)—a number result-
ing from the normalization procedure; values are the mean ± SEM 



















































































































Fig. 3  The effects of haloperidol (5 and 20 µM), olanzapine (5 and 
20 µM) and amisulpride (20 and 100 µM) on VPAC2 expression in 
T98 cell line. Cells were incubated with neuroleptic drugs for 24  h 
(a, b) or 72 h (c, d) and subjected to gene expression studies. Con-
trol cells were treated with medium. 1 µg of total RNA isolated from 
cells was reverse transcribed and 50  ng of cDNA was used for the 
real-time PCR analysis. All real-time PCR reactions were performed 
in duplicate, using ACTB gene as an endogenous normalization fac-
tor. Results are expressed as relative units (r.u.)—a number result-
ing from the normalization procedure; values are the mean ± SEM 
(n = 8). Statistical differences are shown as *p < 0.05, **p < 0.01 and 
***p < 0.001
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Effect of PACAP38 and Forskolin on Cyclic AMP 
Formation in T98G Cells
As shown in Fig.  5, PACAP38 stimulated cAMP produc-
tion in T98G cells in a dose-dependent manner, reaching a 
maximal effect at 1  µM. Forskolin, a diterpene derivative 
acting directly on the catalytic domain of AC was used as 
reference.
Discussion
Neuroleptic drugs are well-known for their therapeu-
tic efficacy in schizophrenia, but their exact mechanism 
of action is still disputed. Although it is known that they 
alter dopaminergic and serotonergic neurotransmission, 
the molecular mechanisms underlying the clinical efficacy 
of typical and atypical antipsychotics in schizophrenia are 
largely unknown. However, their influence on neurotrophic 
factors is intriguing. Numerous studies have examined the 
short- and long-term effects of antipsychotics on the syn-
thesis and secretion of such neuropeptides as nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF) or 
glial cell line–derived neurotrophic factor (GDNF), which 
are very important neuroregulators in the etiology and 
treatment of schizophrenia [8, 25, 26].
However, few reports have examined the effect of neuro-
leptics on the PACAP signaling pathway. Hyperlocomotion 
and jumping behavior were attenuated effectively by halop-
eridol (a D2 antagonist) in PACAP deficient mice, but not 
deficits in prepulse inhibition (PPI) [27, 28]. Risperidone, 
a combined D2 and 5-HT2A receptor antagonist, reversed 
both hyperactivity and diminished PPI in PACAP−/− mice 
to the level observed in wild-type mice [19]. These studies 
indicate the presence of an interaction between the PACAP 
system and the dopaminergic and serotoninergic systems. 
In addition, it has been clearly confirmed that PACAP may 
play an important role in psychological disease, and that the 
regulation of PACAPergic signals could represent a poten-
tial target for the pharmacological treatment of such psy-
chiatric states as schizophrenia or bipolar disease [10, 19, 
29]. However, before these new drugs enter clinical prac-
tice, it is important to determine how existing neuroleptics 
affect the activity of the PACAPergic pathway. As PACAP 
and its receptors are known to be involved in the mecha-
nism of antidepressant action [30], the aim of this work was 
to investigate the effect of neuroleptic drugs used in clinical 
practice on the expression of genes coding PACAP and VIP 
peptides and their receptors in the nerve cells.
Three antipsychotic drugs with different mechanisms of 
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Fig. 4  The effects of PACAP38 on PAC1 (a) and VPAC2 (b) expres-
sion in T98 cell line. Cells were incubated with PACAP38 for 24 h 
or 72  h and subjected to gene expression studies. Control cells 
were treated with medium. 1  µg of total RNA isolated from cells 
was reverse transcribed and 50  ng of cDNA was used for the real-
time PCR analysis. All real-time PCR reactions were performed in 
duplicate, using ACTB gene as an endogenous normalization factor. 
Results are expressed as relative units (r.u.)—a number resulting from 
the normalization procedure; values are the mean ± SEM (n = 8). Sta-
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Fig. 5  Effects of PACAP38 and forskolin (a direct activator of AC) 
on cyclic AMP formation in T98G cells. Results are expressed as the 
mean ± SEM (n = 3–13) and show percent of respective control value. 
Statistical differences are shown as **p < 0.01 and ***p < 0.001
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haloperidol, an atypical one, represented by olanzapine, 
and amisulpride. The T98G cells were exposed to 5 and 
20 µM concentrations of the tested drugs and incubated for 
24 or 72 h. These concentrations were chosen based on the 
literature and our own cell viability measurements (Fig. 1) 
[31, 32]. Although these concentrations may seem high 
compared to the therapeutic plasma levels, they are simi-
lar to the concentrations of antipsychotic drugs (1–25 µM) 
that cause GDNF release from C6 cells [25] and to the con-
centrations of antidepressants (1–10 µM) that alter PACAP 
mRNA receptors in rat primary cortical neurons [30]. 
Human glioblastoma cells are used as an example of glial 
cells in in vitro studies because of their functional similar-
ity to normal astrocytes [7, 33, 34]. Our findings indicate 
that PACAP38 dose-dependently increased AC activity in 
both T98G cell membranes and astrocytes (Fig.  5) [23]. 
Previous studies have also used brain tumor cells to study 
the regulation of PACAP gene expression [35–38].
The present paper is the first to demonstrate of the 
expression of PAC1- and VPAC2-subtype PACAP recep-
tors in the T98G human glioblastoma cell line. The expres-
sion of the PAC1 and VPAC2 receptors in this type of 
cells was surprising, taking into account literature data. 
In contrast, a previous rt-PCR examination of the mRNA 
of T98G cells only identified the presence of the VPAC2 
mRNA receptor, which may be attributed to their use 
of a less sensitive method [35]. Therefore, the T98G cell 
line was selected as a suitable model for the study of the 
action of neuroleptic drugs or exogenous PACAP on PAC1/
VPAC-type receptor gene expression.
The treatment of schizophrenia is difficult because of the 
complex and not fully understood etiology of the disease, 
although the dopamine, serotonin and glutamate hypothe-
ses are the best known [39, 40]. Another pathophysiological 
phenomenon associated with schizophrenia is the abnor-
mality in PACAPergic signals, which is present upstream 
of the regulation of dopaminergic, serotoninergic and glu-
tamergic systems. The hypofunction of the PACAP system 
leads to the activation of the dopaminergic and serotoner-
gic systems, and the inactivation of the glutamergic system 
[10]. Therefore, a potentially valuable target for schizo-
phrenia treatment could be the regulation of PACAP recep-
tors, though which the peptide exerts its neurotrophic and 
neuroprotective potency; one such destination being glial 
cells, which are involved in neural communication: another 
element attenuated in the schizophrenic brain. Recent stud-
ies on humans reported that genetic variants of the PACAP 
and PAC1 genes are associated with schizophrenia and that 
the risk of single nucleotide polymorphism (SNP) of these 
genes could be associated with reduced hippocampal vol-
ume and poorer memory performance [19].
Studies indicate that disturbances of PACAP func-
tion might be associated with schizophrenia, and PACAP 
knockout mice (PACAP−/− mice) could be a possible ani-
mal model for examining schizophrenia. PAC1 receptor-
deficient mice have also exhibited abnormal behavior 
[41]. Interestingly, PAC1-overexpression mice have been 
reported to display strikingly similar phenotypes to PAC1 
knockout mice [42], suggesting that the changes in the 
expression of PACAPergic signaling observed in schizo-
phrenic patients seem to be very complex, and associated 
with defects or overexpression of PAC1. The conventional 
drugs which are used to treat schizophrenia or potential 
candidates may restore the normal conditions for PACAP-
PAC1 signaling in the brain, perhaps by acting like partial 
agonists [43].
Our findings indicate that 24-h incubation with 20 µM 
haloperidol and olanzapine caused a statistically significant 
reduction of PAC1 mRNA expression; however, the effect 
was not maintained after prolonged treatment with drugs, 
and haloperidol even up-regulated PAC1 mRNA expres-
sion in a dose-dependent manner. It was found that 5 µM 
haloperidol administration resulted in 1.8-fold greater 
PAC1 mRNA expression than controls, while 20 µM halo-
peridol was associated with a 2.5-fold increase. The influ-
ence of amisulpride on PAC1 mRNA was not statistically 
significant.
Longer incubation times with haloperidol or olanzap-
ine were associated with the opposite effect on PAC1 gene 
expression; as neuroleptics are used for longer than 24-h 
periods, the obtained results concerning 72-h incubation 
with drugs should be taken into consideration. Although 
the results from in vitro studies cannot be easily transferred 
to in vivo studies, it is possible that the effect observed in 
the cell cultures exposed to neuroleptic drugs for 72 h may 
be related to the delayed effect observed in the animal and 
clinical studies. It seems to be consistent with findings that 
the mechanisms by which neuroleptics produce their thera-
peutic effects (seen after a few weeks of continuous treat-
ment) must involve the chronic regulation of various sec-
ond messenger systems following the immediate receptor 
blockade [8]. Therefore, it is possible that the increase of 
mRNA PAC1 expression, i.e. the first step of the PACAPer-
gic pathway, by haloperidol and olanzapine may influence 
the PACAP/PAC1 receptor system in glial cells, e.g. acti-
vation of cAMP/protein kinase A (PKA)-dependent signal-
ing pathways, which are important in appropriate astrocyte 
function (differentiation, maturation, glutamate turnover or 
antioxidant protection) [44, 45]. Disturbances of these reg-
ulatory mechanisms in glial cells could represent a major 
cause for neurological and psychiatric disorders [1]. There-
fore, the positive modulation of cAMP signaling may pro-
mote the normal state of differentiated astrocytes and favor 
the protection and function of neuronal networks.
A strong genetic link exists between schizophre-
nia and VPAC2 receptors: two recent publications from 
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independent groups found that schizophrenia was asso-
ciated with the presence of an increased number of the 
gene copies encoding the VPAC2 receptor, caused by 
duplications of the 7q36.3 chromosomal region VIPR2 
[20, 21]. This copy number increase was associated with 
the elevated gene expression and activity of VPAC2 
in cells lines carrying the duplication. Such a selective 
antagonist of VPAC2 receptors could offer therapeutic 
potential in the treatment of patients who carry dupli-
cation of the VPAC2 region. Our findings indicate that 
20 µM haloperidol, 20 µM olanzapine and 100 µM ami-
sulpride decreased VPAC2 mRNA expression, especially 
after 72-h incubation, with haloperidol being distinctly 
more potent than atypical neuroleptic drugs. A 24-h incu-
bation with 20 µM haloperidol resulted in 20% decreased 
VPAC2 mRNA expression with the effect reduced by 
65% after prolonged treatment. Olanzapine decreased the 
VPAC2 expression by approximately 30%, and amisul-
pride by 16%. To date, no studies have been conducted to 
demonstrate the relationship between schizophrenia and 
VPAC1 receptors.
The literature data indicates that the perfect neuroleptic 
drug should inhibit VPAC2 mRNA expression and restore 
the appropriate balance of PAC1 receptor expression in dif-
ferent regions of the brain [20, 21, 41, 42]. The tested drugs 
seem to meet these criteria, at least when it comes to the 
VPAC2 receptors, which are overexpressed in schizophre-
nia. All of the tested drugs inhibited VPAC2 after long-
term treatment, albeit limited by in vitro studies, and this 
effect could be a direction for future neuroleptics to take 
regarding their therapeutic activity. An opposite effect 
was observed concerning PAC1 receptor expression: after 
72-h incubation, haloperidol and olanzapine increased the 
mRNA level of PAC1 receptors, but amisulpride slightly 
inhibited expression at a lower concentration and had no 
effect at a higher concentration. Haloperidol, a typical 
neuroleptic, was more potent in increasing PAC1 mRNA 
expression and inhibiting VPAC2 mRNA expression than 
the tested atypical neuroleptics. The diverse potency of 
typical and atypical antipsychotics on the mRNA level of 
PAC1 and VPAC2 receptors may explain the differences 
in their therapeutic efficacy used for treating patients with 
schizophrenia.
Moreover our findings indicate that glial cells may be a 
possible target site of action of neuroleptics. This hypoth-
esis is particularly important when considering that glial 
cells are more numerous than nerve cells in the brain, and 
abnormal neuronal network formation and neural trans-
mission are common in schizophrenia [1, 2]. PACAP is 
involved in both neuronal transmission and neuronal devel-
opment, suggesting that the regulation of the PACAP sys-
tem through glial cells might be one of the strategies for the 
treatment of schizophrenia [10].
The study also examined the effect of exogenous 
PACAP38 on the expression of its specific receptors as ref-
erence to the neuroleptic drugs. A slight up-regulation of 
PAC1 mRNA was observed after a 24-h incubation with 
PACAP38. This effect was also noted after a further 72 h of 
treatment with peptide. A similar situation was noticed for 
VPAC2 protein level: PACAP38 incubation produced a sig-
nificant six-fold increase of VPAC2 mRNA expression after 
a 24-h incubation, although this effect was weaker after 
72  h. The molecular basis of the observed positive feed-
back mechanism can be explained by the fact that PACAP 
as a neuropeptide with pleiotropic potency by increasing its 
specific receptors enhances PACAP signaling system. The 
obtained results correspond with previous studies, which 
note that PACAP increased PAC1 receptor expression in 
LβT2 gonadotroph cells [46]. Moreover, PACAP stimulates 
the expression of its own mRNA in PC12 cells as well as 
cultured rat cortical neurons [47]. It has been suggested that 
the expression of PACAP and its receptors may be upregu-
lated by PACAP via an autocrine mechanism, and that the 
role of endogenous PACAP is to promote the survival of 
nerve cells [48, 49]. It is worth noting that, similar to exog-
enous PACAP38, the neuroleptic drugs tested in the pre-
sent study also increased PAC1 mRNA expression, which 
can contribute to a neuroprotective mechanism of action. 
This finding correlates with recent observations that antip-
sychotics not only act on dopaminergic and serotoninergic 
neurotransmission but with prolong treatment may also 
influence neurotrophic and other growth-related factors [7, 
8, 25].
The study does have some limitations. First, the expres-
sion of the genes was tested in only one cell line, glioblas-
toma T98G, which may be regarded as of limited relevance 
to the brain pathology observed in schizophrenia. Second, 
changes in mRNA levels do not necessarily mean altera-
tions in protein levels. Follow-up experiments to meas-
ure the expression of PAC1 and VPAC2 protein levels are 
needed to provide supporting data.
In conclusion, the present work provides the first con-
firmation of the influence of neuroleptic drugs on the 
expression of genes encoding the PAC1/VPAC type recep-
tors in T98G cells. The tested antipsychotics differentially 
regulated the changes in PACAP receptor levels depend-
ing on the concentration and incubation time: While all 
drugs inhibited VPAC2 mRNA expression after long-term 
treatment, only haloperidol and olanzapine up-regulated 
PAC1 receptor mRNA expression. Our findings offer a 
completely new perspective on the neuroprotective mecha-
nism of action of antipsychotics and open new opportuni-
ties for novel therapeutic targets. Although antipsychotics 
are the best treatment of schizophrenia currently available, 
they have many side effects, such as extrapyramidal side 
effects. A new strategy to avoid these side effects may be 
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by exploiting the regulation of PACAPergic pathway. A key 
advantage of PACAP therapy is that it enhances not only 
dopaminergic and serotonergic transmission, but also neu-
ronal activity, a mechanism which may improve efficacy 
to a greater degree than traditional treatment strategies; a 
quality which is the cornerstone of effective schizophrenia 
therapy.
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